Judges Scientific plc AIM:JDG UHV Design 2011 Quorum 2014 - - PowerPoint PPT Presentation

judges scientific plc
SMART_READER_LITE
LIVE PREVIEW

Judges Scientific plc AIM:JDG UHV Design 2011 Quorum 2014 - - PowerPoint PPT Presentation

Judges Scientific plc AIM:JDG UHV Design 2011 Quorum 2014 Scientifica 2014 Scientifica 2012 GDS 2011 22 March 2016 Disclaimer The document attached hereto and the presentation of which it forms part (together the Materials) have been


slide-1
SLIDE 1

UHV Design 2011 GDS 2011 Quorum 2014 Scientifica 2012 Scientifica 2014

Judges Scientific plc

AIM:JDG

22 March 2016

slide-2
SLIDE 2

Disclaimer

The document attached hereto and the presentation of which it forms part (together the “Materials”) have been prepared by Judges Scientific plc (“Judges” or the “Company”) and are confidential and personal to you and the Materials are furnished to you as background information to provide a basis for potential investors to consider whether to pursue an acquisition of shares in the Company and do not constitute an offer or invitation for the sale or purchase of any securities, nor do they, nor do they purport to, set out or refer to all or any of the information an investor might require or expect in making a decision as to whether or not to deal in shares in the Company. The Materials do not constitute and are not a prospectus or listing particulars (under the Financial Services and Markets Act 2000 (“FSMA”) or the Prospectus Rules of the Financial Services Authority) nor do they comprise an AIM admission document for the Rules of AIM operated by the London Stock Exchange plc and should not be construed as such. No representation or warranty or other assurance, express or implied, is made by or on behalf of or the Company or any of their respective directors, officers, employees, advisers or any

  • ther persons as to the fairness, accuracy or completeness of the information or estimates or opinions or other statements about the future prospects of the Company or any of its

respective businesses contained in the Materials or referred to in the presentation given in connection therewith and no responsibility, liability or duty of care whatsoever is accepted by any such person in relation to any such information, projection, forecast, opinion, estimate or statement. Members of the public are not eligible to take part in the presentation or be provided with the Materials. In the United Kingdom, the Materials are only being directed at persons (i) reasonably believed by the Company to be investment professionals within the meaning of paragraph (5) of Article 19 or to high net worth companies or unincorporated associations within the meaning of paragraph (2) of Article 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529), as amended and (ii) who are “qualified investors” within the meaning of section 86(7) of FSMA or otherwise in circumstances that will not have resulted and will not result in an offer of transferable securities to the public in the United Kingdom within the meaning of section 102B of FSMA. The investment or investment activity to which the Materials relate are available only to such persons and will be engaged with only with such persons. If you are not such a person (i) you should not take part in the presentation and nor should you have received the Materials, (ii) please return this document to the Company’s registered office or representative at the presentation as soon as possible and take no other action, (iii) please leave the presentation immediately after returning the Materials and (iv) you may not rely on or act upon the matters communicated by the Materials. This presentation and the information contained herein are not for publication or distribution in the United States (within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). The securities offered by the Company have not been and will not be registered under the Securities Act or any state securities laws in the United States. The securities may not be offered or sold in the United States or to or for the account or benefit of U.S. Persons (as defined in regulation S) except that the securities may be offered or sold to persons who are "qualified institutional buyers" (as defined under Rule 144A under the Securities Act) in reliance on exemption from the Securities Act provided by Rule 144A and otherwise in accordance with the applicable laws of any US State. Offers and sales to non-US Persons will be made only in "offshore transactions" in reliance on Regulation S. Neither this presentation nor any copy of it or any of the Materials may be taken or transmitted into or distributed in Canada, Australia, or the Republic of South Africa or to any resident thereof, or (iv) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this document in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. The Materials are being made available on the basis that the recipients keep confidential any information contained therein, whether orally or in writing, in connection with the

  • Company. The Materials are confidential and must not be copied, reproduced, published, distributed, disclosed or passed to any other person at any time without the prior written

consent of the Company. This presentation contains forward looking statements. These forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events. These forward-looking statements are subject to risks and uncertainties. These risks and uncertainties could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. This presentation is intended for informational purposes and does not constitute an offer to sell securities in any jurisdiction.

1

slide-3
SLIDE 3

2

Overview

  • Group involved in the buy and build of scientific instrument businesses
  • Twelve acquisitions since May 2005
  • Continued opportunities for consolidation in fragmented market
  • Long-term profitability and cash generation
  • Strong growth fundamentals in resilient core markets; UK is centre of manufacturing excellence

500 1000 1500 2000 2500 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Share performance

LSE: JDG FTSE: ASX

5 Queen’s Awards for design excellence and export

p

slide-4
SLIDE 4

Highlights – FY 2015

Financial

  • Record revenues of £56.2m (2014: £40.6m); 4.9% organic growth
  • Opening order book 11.9 weeks (2014: 9.9 weeks); organic order intake up 12.7%
  • Adjusted operating profit: £9.3m (2014: £7.0m); up 32.9%
  • Adjusted basic EPS: 109.2p (2014: 82.7p), up 32.0%
  • Total 2015 dividend of 25.0p; 14% increase on 2014
  • Cash generated from operations of £8.5m (2014: £7.5m)
  • Adjusted net debt of £4.0m (Dec 2014: £1.3m)

Operating

  • 2 acquisitions completed since Jan 2015
  • Benefits from streamlined banking arrangements

3

slide-5
SLIDE 5

Management team

Alex Hambro, Non-Executive Chairman Experienced adviser to private equity and VC funds and family office investors. David Cicurel, Chief Executive Founded Judges in 2002; Turnaround specialist and veteran deal-maker Brad Ormsby, Group Finance Director Previously CFO of Kalibrate Technologies plc; PwC trained Chartered Accountant David Barnbrook, Chief Operating Officer Chartered Engineer with over 20 years senior management experience in industry 4

Owners of 19% of equity

slide-6
SLIDE 6
  • Long term drivers of growth:

– Global higher education – Optimisation

  • Acquisition attributes:

– Strong exporters in their global niche markets; solid EBIT margins – Generate sustainable profits and cashflows – Pay 3 to 6 times EBIT according to size – Borrow up to 2.5 times EBITDA @ 2 to 4%

  • Post acquisition:

– Create environment for businesses to thrive; implement robust financial controls – Repay debt and reinvest in further acquisitions 5

Our Business Model

slide-7
SLIDE 7
  • 10.0

20.0 30.0 40.0 50.0 60.0

b c d e f g h i j k l m n

  • p

q r s t u v

  • 1.0

2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0

Revenues £m Profits £m

Revenues and Profits

Revenue £m Adjusted operating profit

11 Year Financial History

6 Faster debt repayment

  • 20.0

40.0 60.0 80.0 100.0 120.0

b c d e f g h i j k l m n

  • p

q r s t u v w

  • 5.0

10.0 15.0 20.0 25.0 30.0

  • Adj. EPS (p)

Dividends (p)

EPS and Dividends

Adjusted EPS Dividend

  • 1.0

2.0 3.0 4.0 5.0 6.0 7.0 £'m

Annual debt repaid + dividends paid from cashflow

Dividends Repayment of borrowings

CAGR 9.4% for past 8 years

slide-8
SLIDE 8

Operational results drivers

  • Organic revenue

– public sector funding – foreign exchange rates – macroeconomic environment

  • Cost

– investment in R&D and sales – control of other overheads

  • Geographic expansion

– Armfield’s US office – new Scientifica office adjacent 7

slide-9
SLIDE 9

Segmental split

Material sciences 50% of Group sales 53% of EBITA contribution

  • Businesses acquired:

Armfield: educational instruments and R&D instruments for food and drinks 8

FTT Sircal PFO GDS Armfield

Revenue

Vacuum 50% of Group sales 47% of EBITA contribution

  • Businesses acquired:

CoolLED: LED illumination sources for fluorescence microscopy

Revenue

Quorum Scientifica UHV Deben

slide-10
SLIDE 10

Armfield acquisition

  • Educational (c.75% sales); R&D for food and drinks (c.25% sales)
  • Reputation for high quality products and service
  • £9.6m acquisition cost (approx 5 times earnings)
  • Financed with £5m from new acquisition facility
  • Performing in line with expectations
  • Earnings enhancing and cash generative

9

slide-11
SLIDE 11

CoolLED acquisition

  • LED illumination sources for fluorescence microscopy
  • High quality products leading the replacement of mercury lamps
  • £2.8m revenues and £0.75m operating profit
  • Consideration consists:

– £3.5m cash paid on completion – Earn-out capped at £1.0m based upon operating profits of £1.0m

  • Financed by £3.5m from revolving acquisition facility
  • Immediately earnings-enhancing
  • Management team remaining

10

slide-12
SLIDE 12

Acquisitions overview

  • Fragmented market with over 2,000 privately held businesses in the UK
  • Large pool of potential acquisitions; Judges is highly selective
  • Judges has strong reputation for being a good acquirer:

– Trusted to honour the terms agreed – Trusted to act quickly with secured funding – Treats vendors and staff with respect – No micromanagement post-acquisition

10

11

slide-13
SLIDE 13

2015 2014 Variance Variance £m £m £m % Revenue 56.2 40.6 15.6 38.5% Operating costs (46.9) (33.6) (13.3) 39.6% Adjusted operating profit 9.3 7.0 2.3 31.9% Interest (0.5) (0.6) 0.1 (16.7)% Adjusted PBT 8.8 6.4 2.4 35.6% Taxation (1.8) (1.2) (0.6) 46.1% Adjusted PAT 7.0 5.2 1.8 33.2% Adjusting items (post tax) (5.9) (2.9) (3.0) 102.8% Statutory PAT 1.1 2.3 (1.2) (52.6)%

Performance

Organic revenue up 4.9% Adjusted PBT up 35.6% Adjusting items mainly amortisation from Armfield acquisition (inc. £2m

  • f order backlog asset)
  • Performance weighted to H2 for first time – Armfield and sales recovery
  • Effective tax rate impacted by Armfield US; new Scientifica US office from 2016

12

slide-14
SLIDE 14

Revenue summary

  • Record revenues of £56.2m up £15.6m
  • 4.9% like for like sales growth
  • Organic growth UK, US; China strong; EU slow
  • 5/6ths sales exported
  • Armfield’s higher RoW revenues
  • Seasonality for the first time:

13

UK Europe North America Rest of the world

  • 4,000

8,000 12,000 16,000 20,000 24,000 Sales 2014 Sales 2015

  • 30.0%
  • 10.0%

10.0% 30.0% 50.0%

Organic sales 2015

£’000

H1 H2

Half year split

H1 H2

Impact on EPS

slide-15
SLIDE 15

ORDER INTAKE

  • FY Organic order intake ahead by 12.7% compared to 2014
  • YTD intake quiet; similar to start of 2014 and 2015
  • Organic order book at 31 Dec 2015: 11.4 weeks (1 Jan 2015: 9.9 weeks)

14

Total order book 11.9 weeks including Armfield

10,000 20,000 30,000 40,000 50,000 60,000 70,000 Thousands Group (17 wks * 3) Group (ttm) Group (budget)

slide-16
SLIDE 16

Cashflow 2015 2014 £m £m Adjusted EBITDA 9.7 7.4 Working capital movements (0.5) 0.1 Share based payments 0.1

  • DB pension contributions

(0.2)

  • Exceptional transaction fees

(0.6)

  • Cash generated from operations

8.5 7.5 Tax (1.4) (1.2) Capex (inc acquisitions) (8.1) (0.7) Interest payments (0.5) (0.6) Repayment of borrowings (4.6) (2.7) Proceeds from bank loans 4.8

  • Dividends

(1.4) (1.2) Issue of shares 0.2 0.1 Other (0.1) (0.2) Movement in cash (2.6) 1.0

Summary Balance sheet and Cashflows

Continued low working capital Inherited Armfield Defined Benefit pension scheme Healthy cash generation Focus on debt repayment Increasing dividend returns for shareholders

15

Balance Sheet 2015 2014 £m £m Cash 8.5 11.1 Debt (12.5) (12.4) Adjusted net debt (4.0) (1.3) Minority debt (0.5) (0.5) Working capital 6.7 5.1 DB Pension (1.1)

  • Other assets/liabilities

23.0 20.0 Net assets 24.1 23.3

Net debt higher following £9.6m Armfield acquisition

slide-17
SLIDE 17

Return On Total Invested Capital

16

0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% 40.0% 45.0% 50.0%

ROTIC (Trailing 12 months)

GDS acquisition March 2012 Scientifica June 2013 FTT acquisition Armfield January 2015

slide-18
SLIDE 18

Investment case

  • Robust business model; pursued with discipline
  • Strong long-term growth drivers in higher education and optimisation
  • Management focused on shareholder value - cash generation, debt

repayment, dividend growth and return on capital

  • Every deal is earnings enhancing; large pool of targets
  • Dividend growth of 10+% for past 11 years
  • Inheritance tax free shareholding after 2 years

17

slide-19
SLIDE 19

Appendices

  • Capital structure
  • Trading businesses

18

slide-20
SLIDE 20

Capital Structure

Listing & Ticker: AIM : JDG Ordinary Shares Issued (18.3.15): 6,100,549 Last price (17.3.15): 1572.5p Market Capitalisation (18.3.15): £95.9m Major shareholders:

15.0% - David Cicurel 3.7% - Other directors 11.0% - Schroders 7.2% - Liontrust Asset Management 5.5% - Guy Naggar 4.9% - FTT Vendors 4.9% - Polar Capital 2.7% - Hargreaves Lansdown 2.6% - NFU Mutual 2.3% - Allianz Asset Management AG 1.7% - Artemis Asset Management Ltd 1.6% - Incagrove Ltd

19

slide-21
SLIDE 21

Subsidiary companies

20

slide-22
SLIDE 22

Fire Testing Technology (FTT)

  • Purchased in 2005
  • Instruments measure

materials’ reaction to fire

  • World leader
  • Driven by safety, regulation,

globalisation

21

slide-23
SLIDE 23

PE.fiberoptics (PFO)

  • Judges backed MBO in 2005;

51% holding

  • PerkinElmer closed it when the

internet bubble burst

  • Management remain
  • Instruments measure behaviour
  • f light in fibre (telecom)
  • Driven by growth of the internet

22

slide-24
SLIDE 24

Sircal

  • Purchased in 2010
  • Instruments to purify noble

gases

  • Used in Arc-Spark

spectrometry to analyse metals

  • Driven by global growth and

regulation

23

slide-25
SLIDE 25

Global Digital Systems (GDS)

  • Acquired March 2012
  • Geotechnical instruments
  • Measure mechanical properties of soil

and rock

  • Largely universities but increasing

sales to commercial sector

24

slide-26
SLIDE 26

UHV Design

  • Purchased in 2006
  • Instruments move, heat and cool
  • bjects under Ultra High Vacuum
  • Universities, science projects, some

manufacturing

  • Driven by growth in science and

education

25

slide-27
SLIDE 27

Quorum

  • Purchased in 2009
  • Instruments used to prepare

samples for electron microscopy

  • Universities, bioscience,

semiconductors

  • Driven by growth in education

and life sciences

26

slide-28
SLIDE 28

Deben

  • 51% purchased March 2011
  • KE added in 2012
  • Management stayed on with 49%
  • Accessories used in electron

microscopy

  • Universities and electron

microscope OEMs

27

slide-29
SLIDE 29

Scientifica

  • Purchased in 2013
  • Electrophysiology and imaging
  • Systems used in neuroscience research
  • Driven by efforts to find cures for

degenerative conditions

  • Universities & research centres in US, UK

and elsewhere

28

slide-30
SLIDE 30

Armfield

  • Acquired in Jan 2015
  • Educational instruments for

undergraduate students

  • R&D instruments for commercial food

and drinks industry

  • Worldwide agents network
  • Vendor management team remain

29

slide-31
SLIDE 31

CoolLED

  • Purchased in February 2016
  • LED illumination sources for

fluorescence microscopy

  • Replacement for outdated

mercury lamps

  • Universities & research

centres in US, UK and elsewhere

  • Management team remaining

30